Fig 8.

Effects of pharmacological inhibitors on BZLF1 expression in Akata and B95-8 cells. Akata or B95-8 cells were treated with either vehicle (Control), 10 μM DZNep (DZ), 300 nM Trichostatin A (TSA), 1 μM 5-aza-2′-deoxycytidine (5Az), or in combinations as indicated. As positive controls (PC), Akata cells were treated with anti-IgG (10 μg/ml), and B95-8 cells were treated with 20 ng/ml TPA, 1 μM A23187, and 5 mM sodium butyrate. For DZNep or 5Az treatment, cells were exposed to the reagent daily for 3 days. Treatments with other chemicals were conducted for 24 h. Real-time RT-PCR was carried out as described in Materials and Methods. Levels of BZLF1 (upper panels) and EBNA2 (lower panels) mRNAs were normalized to GAPDH mRNA levels and are shown as fold increase. Each bar represents the means and SD from three independent treatments.